-
公开(公告)号:WO03045901A3
公开(公告)日:2003-07-31
申请号:PCT/GB0300339
申请日:2003-01-28
Applicant: CELLTECH R&D LTD , DYKE HAZEL JOAN , BUCKLEY GEORGE MARTIN
Inventor: DYKE HAZEL JOAN , BUCKLEY GEORGE MARTIN
IPC: A61P35/02 , C07D263/32 , C07D413/12 , C07D417/12 , A61K31/421 , A61K31/422 , A61K31/427
CPC classification number: C07D413/12 , C07D263/32 , C07D417/12
Abstract: Guanidine derivatives of formula I are described: wherein: R' is an aliphatic, cycloaliphatic or cycloalkyl-alkyl- group R2 is an optionally substituted aromatic, heteroaromatic group, aryl-fused cycloaliphatic, heteroaryl-fused cycloaliphatic, aryl-fused heterocycloaliphatic or heteroaryl-fused heterocycloaliphatic group R3 is a -CN, -COR5, -OR6, -CONR7R8, S02R5 or S02NR7R8 group R4 is an optionally substituted heteroaromatic group and the salts, solvates, hydrates, tautomers, isomers, N-oxides thereof. The compounds are potent inhibitors of IMPDH and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatic and anti-viral agents.
Abstract translation: 描述了式I的胍衍生物:其中:R'是脂族,脂环族或环烷基 - 烷基 - 基团,R2是任选取代的芳族,杂芳族基团,芳基稠合的脂环族,杂芳基稠合的脂环族,芳基稠合的杂环脂族基或杂芳基 - 稠合的杂环脂族基团R 3是-CN,-COR 5,-OR 6,-CONR 7 R 8,SO 2 R 5或SO 2 NR 7 R 8基团,R 4是任选取代的杂芳族基团及其盐,溶剂合物,水合物,互变异构体,异构体,N-氧化物。 该化合物是IMPDH的有效抑制剂,并且可用作免疫抑制剂,抗癌剂,抗炎剂,抗银屑病剂和抗病毒剂。
-
公开(公告)号:ES2273278T3
公开(公告)日:2007-05-01
申请号:ES04742999
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
Inventor: OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: C07D211/96 , A61K31/451 , A61P37/00
Abstract: Un compuesto de fórmula (1): en la que: Ci es un grupo arilo o heteroarilo; m es cero o el número entero 1, 2 ó 3; n es cero o el número entero 1, 2 ó 3; en el que la suma de m y n es cero o el número entero 1, 2 ó 3; R1 es un grupo seleccionado de alquilo C1-6, arilo, heteroarilo, heterocicloal- quilo, cicloalquilo C3-6, -alquil C1-6-arilo, -alquil C1-6-heteroarilo, - alquil C1-6-heteroci- cloalquilo o -alquil C1-6-cicloalquilo C3-6, en el que cada grupo arilo o heteroarilo, pre- sente como grupo R1 o como parte del mismo, puede estar sustituido opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo R7, en el que cada R7 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, Cl, Br, alquilo C1-6, haloal- quilo C1-6, alcoxi C1-6, haloalcoxi C1-6, -CN, -CO2R7a, -CON(R7a)2 o -COR7a; y en el que cada grupo alquilo, heterocicloalquilo o cicloalquilo, presente como grupo R1 o como parte del mismo, puede estar sustituido opcionalmente con 1, 2 ó 3 sustituyentes se- leccionados del grupo R8, en el que cada R8 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, =O, =NOR10, -CO2R8a, -CON(R8a)2 o -COR8a; R7a, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno, o un grupo alquilo C1-6 o haloalquilo C1-6; R8a, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno, o un grupo alquilo C1-6 o haloalquilo C1-6; R10 es un átomo de hidrógeno o un grupo alquilo C1-3; R2 es un átomo de hidrógeno o un grupo alquilo C1-3; o R1 y R2 junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo C3-6 o heterocicloalquilo sustituido opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo R9, en el que cada R9 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, =O, =NOR10, -CO2R8a, -CON(R8a)2 o -COR8a; R3 es un átomo o grupo seleccionado de F, Cl, Br, alquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3 o -CN; R4 es un átomo de hidrógeno, F, Cl o Br o un grupo alquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3, -CN, -SO2R5, -SO2N(R6)2, -CON(R6)2, -N(R6)2, -NHSO2R5 o - NHCOR5; R5 es un grupo alquilo C1-3; R6, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno o un grupo alquilo C1-3; y Ra y Rb, que pueden ser iguales o diferentes, son cada uno un átomo o grupo seleccionado de hidrógeno o alquilo C1-3, o Ra y Rb pueden estar unidos para formar un grupo cicloalquilo C3-6 o heterocicloalquilo como se definió para R1 y R2; y sus sales, solvatos, hidratos, tautómeros, isómeros o N-óxidos.
-
公开(公告)号:CA2528316A1
公开(公告)日:2004-12-29
申请号:CA2528316
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
Inventor: ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN , OWEN DAVID ALAN , WATSON ROBERT JOHN
IPC: C07D211/96 , A61K31/451 , A61P37/00
Abstract: A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention o f allergic, inflammatory and neoplastic diseases.
-
公开(公告)号:HU0401187A2
公开(公告)日:2004-12-28
申请号:HU0401187
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号:BR0211780A
公开(公告)日:2004-07-27
申请号:BR0211780
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号:DE602004003256D1
公开(公告)日:2006-12-28
申请号:DE602004003256
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
Inventor: OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: C07D211/96 , A61K31/451 , A61P37/00
-
公开(公告)号:EA006877B1
公开(公告)日:2006-04-28
申请号:EA200400287
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE HAZEL JOAN , WARSON ROBERT JOHN
IPC: C07D309/08 , A61K31/445 , A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12
Abstract: Соединениеформулы (I)где Rи R, которыемогутбытьодинаковымиилиразными, представляютсобой, каждый, атомводородаилигруппу CF, CFH или CFH, приусловии, что, когдаодиниз Rили Rпредставляетсобойатомводорода, другойпредставляетсобойгруппу CF, CFH или CFH; иегосоли, сольватыилигидраты. СоединенияявляютсясильнодействующимиингибиторамиММР, которыепреимущественноневызываюттендинитнаприемлемойживотноймодели. Можноожидать, чтосоединенияпригодныдляиспользованияв медицине, особенно, когданеобходимоизбежатьпобочныхдействий, такихкакболив суставах.
-
公开(公告)号:AT318263T
公开(公告)日:2006-03-15
申请号:AT02747621
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号:NZ531521A
公开(公告)日:2005-06-24
申请号:NZ53152102
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE HAZEL JOAN , WATSON ROBERT JOHN
IPC: A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12 , C07D309/08 , A61K31/445
Abstract: A compound of formula (I) that are MMP inhibitors are disclosed wherein: R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided that when one of R1 or R2 is a hydrogen atom the other is a CF3, CF2H or CFH2 group; and the salts, solvates or hydrates thereof. The compounds are potent MMP inhibitors that do not cause tendonitis in a relevant animal model. The compounds may be expected to be of use in medicine, especially where the avoidance of side effects such as joint pain is desired.
-
公开(公告)号:DE602004003256T2
公开(公告)日:2007-05-03
申请号:DE602004003256
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
Inventor: OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: C07D211/96 , A61K31/451 , A61P37/00
-
-
-
-
-
-
-
-
-